Advertisement
Table 1 Patient characteristics at baseline and at 2-year follow-up
| Variable | n | Baseline | At 2-year follow-up |
|---|---|---|---|
| Demographic | |||
| Age (years) | 215 | 57.4 (49.1–64.7) | |
| Female | 215 | 170 (79.0%) | |
| Menopause | 170 | 111 (65.3%) | |
| Body mass index (kg/m2) | 215 | 23.9 (21.3–26.2) | 24.0 (21.5–26.2) |
| Smoker | 210 | 65 (31.0%) | 67 (31.9%) |
| Disease | |||
| Disease duration (years) | 215 | 9 (4–16) | |
| Age at disease onset (years) | 215 | 45.0 (33.0–53.0) | |
| Rheumatoid factor-positive | 202 | 97 (48.0%) | |
| Physician's global assessment score (visual analogue scale, 0–100 mm) | 203 | 19.0 (8.0–39.8) | 17.6 (8.5–30.0) |
| Modified Health Assessment Questionnaire (range 1–4) | 214 | 1.50 (1.13–1.75) | 1.50 (1.13–1.87) |
| Erythrocyte sedimentation rate (mm/hour) | 210 | 16 (9–27) | 14 (8–27) |
| Disease activity score including 28 joints | 202 | 4.04 (3.17–4.96) | 4.26 (3.36–5.06) |
| Medication | |||
| Ever user of disease-modifying antirheumatic drugs | 213 | 177 (83.1%) | 177 (83.1%) |
| Corticosteroids | 208 | 79 (37.9%) | 85 (40.9%) |
| User of corticosteroids in the 2-year period | 208 | 93 (44.7%) | |
| Antiresorptive osteoporosis treatment | 209 | 47 (22.5%) | 68 (32.5%) |
| Ever user of antiresorptive osteoporosis treatment | 209 | 92 (44.0%) | |
| Calcium and/or vitamin D | 210 | 113 (53.8%) | 155 (73.8%) |
